About Forschungszentrum Jülich

Forschungszentrum Jülich pursues cutting-edge interdisciplinary research on solving the grand challenges facing society in the fields of health, energy and the environment, and also information technologies. In combination with its two key competencies – physics and supercomputing – work at Jülich focuses on both long-term, fundamental and multidisciplinary contributions to science and technology as well as on specific technological applications. With a staff of about 4400, Jülich – a member of the Helmholtz Association – is one of the largest research centres in Europe. More and more people are living longer and longer. Jülich health research aims to improve the diagnosis and treatment of age-related diseases of the brain using biophysical methods and imaging techniques. Reliably supplying future generations with environmentally friendly, affordable and secure energy is another research priority at Jülich. Photovoltaics, fuel cells, improved power plant technology and nuclear fusion – these are the fields of work for Jülich’s energy researchers. Conversely, environmental researchers at Jülich are working on the impacts that technological processes have on the environment and the climate. They are investigating how plants react to changing environmental conditions and how food can be provided for a steadily growing global population. Nanoelectronic engineers investigate and develop new materials and manufacturing processes for the computer generation after next. In doing so they pursue three concepts: exploiting the electron spin as a unit of information, developing innovative architectures using proven semiconductor technology, and linking electronic and biological systems. Of major significance in Jülich is simulation research on one of the largest supercomputers in the world.

Facts about Forschungszentrum Jülich
  • Industry : Other

News about Forschungszentrum Jülich

Here you will find Forschungszentrum Jülich GmbH

Last viewed contents

Tumor diagnostics: AI model detects more than 170 types of cancer - Looking into the genome instead of into the tissue

Tumor diagnostics: AI model detects more than 170 types of cancer - Looking into the genome instead of into the tissue

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery - Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery - Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success

Whatman™ folded filter papers | Filter papers | Cytiva

Whatman™ folded filter papers | Filter papers | Cytiva

Start-up aims to harness the natural powers of cancer survivors to cure this life-threatening disease - Cure51 raises a €15 million seed round

Start-up aims to harness the natural powers of cancer survivors to cure this life-threatening disease - Cure51 raises a €15 million seed round

“And the Science Awards go to…” - Bayer Foundation announces Science Awards winners of 2024

“And the Science Awards go to…” - Bayer Foundation announces Science Awards winners of 2024

Supervisory Board of Bayer AG extends contract of CEO Bill Anderson - Far-reaching transformation advancing, delivering first signs of success

Supervisory Board of Bayer AG extends contract of CEO Bill Anderson - Far-reaching transformation advancing, delivering first signs of success

VTU Group appoints Liam O'Neil as new CEO

VTU Group appoints Liam O'Neil as new CEO

Dr. Wolf-Henning Walther becomes new CEO at Metrohm Germany - Change in the Executive Board from September 1, 2025

Dr. Wolf-Henning Walther becomes new CEO at Metrohm Germany - Change in the Executive Board from September 1, 2025

Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector

Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector

Pioneers of epigenetics receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2026 - The prizewinners' discovery shook the foundations of classical genetics and opened the door to the vast field of modern epigenetics

Pioneers of epigenetics receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2026 - The prizewinners' discovery shook the foundations of classical genetics and opened the door to the vast field of modern epigenetics

Melina Schuh honored with Science Breakthrough 2025 - “It has always been my dream to make the entire ovulation process visible”

Melina Schuh honored with Science Breakthrough 2025 - “It has always been my dream to make the entire ovulation process visible”

Kai Beckmann to Succeed Belén Garijo as Chair of the Executive Board and CEO of Merck as of May 2026

Kai Beckmann to Succeed Belén Garijo as Chair of the Executive Board and CEO of Merck as of May 2026